Extended Data Fig. 6. LC improves T cell-based tumor immunotherapy in mice.

a, Li⁺ concentration in blood and tumor interstitial fluids of B16 tumor-bearing mice. n = 3 in LC-blood group and n = 4 in other groups. b-c, Tumor growth and survival of B16/MC38/4T1 tumor-bearing mice gavaged with or without LC once per 2 days. n = 15/10/8 mice in B16/MC38/4T1 model respectively. d, Tumor growth and survival of B16 tumor-bearing mice gavaged with LC/LiCl/Na₂CO₃/NaCl once per 2 days. n = 8 mice. e, Percentage of infiltrating CD8⁺ T cells in B16 tumor, IFN-γ⁺ and CD107a⁺ cells in CD8⁺ TILs at day 18 post tumor injection in mice. n = 8 mice. Data are presented as mean±s.e.m. P values were calculated using one-way ANOVA for Dunnett’s multiple comparisons test (e), two-way ANOVA for Tukey’s multiple comparisons test (d, left), Sidak’s multiple comparisons test for some tumor growth analysis (b), Log-rank test for survival analysis (b, c), and corrected by Bonferroni methods (d, right), ns (not significant).

Source data